Closely held PharmaJet has announced that their WHO-prequalified Tropis ID Needle-free Injection System has been used to deliver more than 25 million needle-free injections in support of polio eradication. According to...
Cognition Therapeutics (NASDAQ: CGTX) has announced alignment with the FDA on key elements of a Phase 3 study of either 100 mg of oral zervimesine or placebo for nine months in mild-to-moderate dementia with Lewy bodies...
BlossomHill Therapeutics (NASDAQ: BLSM) has announced a collaboration with Foundation Medicine, a wholly owned subsidiary of Roche (SIX: RO, ROP; OTCQX: RHHBY), to develop the first companion diagnostic assay (CDx) for...
Lexaria Bioscience (NASDAQ: LEXX) has announced that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) evaluating two oral DehydraTECH-semaglutide (DHT-sema)...
INmune Bio (NASDAQ: INMB) has announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel...
Valion Bio (NASDAQ: VBIO) has shared the initial findings and priorities from Dean Zikria’s first 30 days as interim chief executive officer (CEO). Mr. Zikria’s strategic review has set a focused agenda built on three...
Propanc Biopharma (NASDAQ: PPCB) has announced new preclinical research from an academic–industry collaboration from the Universities of Jaén and Granada, led by Dr. Maria Belén Toledo, that has identified the company’s...
Closely held PharmaJet has announced its participation in a pre-conference panel at the World Vaccine Conference Europe on October 19, 2026, at 14:15. Entitled From Non-Inferiority to Impact: Accelerating Adoption of...
TIME’s Best Innovations of 2026 includes a special mention of Perimeter Medical Imaging AI’s (TSX-V: PINK; OTCQX: PYNKF) Claire OCT System. Claire is the only FDA-approved imaging...
Valion Bio (NASDAQ: VBIO) and closely held LarmorBio today announced that Velocity Bioworks, Valion’s wholly owned biologics contract development and manufacturing organization (CDMO) subsidiary, has successfully...
Edesa Biotech (NASDAQ: EDSA) has announced that the FDA has cleared the company’s Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, enabling Edesa to expand recruitment...
Xenetic Biosciences (NASDAQ: XBIO) has announced that its collaboration partner, closely held PeriNess, has informed the company that the first patient has been dosed in an investigator-initiated clinical study...
Valion Bio (NASDAQ: VBIO) has highlighted the capabilities of its wholly owned contract development and manufacturing organization (CDMO), Velocity Bioworks. Velocity is part of Valion’s own domestic biologics...
Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that five abstracts presented at the 15th Interventional MRI (iMRI) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real...
Organogenesis Holdings (NASDAQ: ORGO) has announced the publication of peer-reviewed trial results in the Journal of Wound Care (JWC) showing the clinical benefit of PuraPly AM for hard-to-treat diabetic foot ulcers...
Cognition Therapeutics (NASDAQ: CGTX) has announced that the United States Patent and Trademark Office (USPTO) has granted a patent covering a novel crystalline form, or polymorph, of zervimesine (CT1812), providing...
Profound Medical (NASDAQ:PROF; TSX:PRN) and Telix Pharmaceuticals (ASX:TLX; NASDAQ:TLX) have entered into a co-education agreement which establishes a framework through which the companies intend to educate urologists...
Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs). This made international headlines earlier this week as...
Co-Diagnostics (NASDAQ: CODX) has announced that it has received an order from the Ute Indian Tribe Mosquito Abatement Department for a full Vector Smart mosquito surveillance laboratory installation. According to Co...
bioAffinity Technologies (NASDAQ: BIAF) has announced that the Japan Patent Office (JPO) has issued a notice of allowance (NOA) indicating its intention to grant a patent covering bioAffinity’s non-invasive lung cancer...
Profound Medical (NASDAQ: PROF; TSX: PRN) announced preliminary unaudited revenues for the third quarter of 2026. The company indicated that its: Total revenue is expected to be in the range of $9.8 million to $10.0...
RenovoRX (NASDAQ: RNXT) has announced that the first patient has enrolled in PRISM-TAMP, an investigator-initiated trial sponsored by the University of Vermont (UVM) evaluating the approved chemotherapy gemcitabine...